Kurkowska Sara, Brosch-Lenz Julia, Dewaraja Yuni K, Frey Eric, Sunderland John, Uribe Carlos
Department of Nuclear Medicine, Pomeranian Medical University, Szczecin, Poland.
Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.
J Nucl Med. 2025 Mar 3;66(3):441-448. doi: 10.2967/jnumed.124.268612.
Individualized radiopharmaceutical therapies guided by patient-specific absorbed dose (AD) assessments using nuclear medicine imaging have the potential to improve both efficacy and safety. Understanding sources of variability in AD calculations is critical for standardization. The Society of Nuclear Medicine and Molecular Imaging Dosimetry Task Force launched the Lu Dosimetry Challenge to evaluate variability across steps within the dosimetry workflow. This work aimed to assess the variability in ADs due to different fitting and integration methods. Anonymized datasets from 2 patients treated with Lu-DOTATATE, including serial SPECT/CT scans, segmented organs and lesions, and time-integrated activity maps, were made available online. Participants were invited to perform dosimetry calculations and submit their results using standardized submission spreadsheets. Fitting approaches were categorized, and relative AD variability was analyzed using the quartile coefficient of dispersion and interquartile range. The variability in AD due to the fitting step for patient A's kidneys was less than 1%. In contrast, patient B's kidneys showed higher variability, with values below 10%. Lesions exhibited more variability in fitting than did kidneys, with variability within 25%. The contribution of variability caused by fitting and integration is small for healthy organs. By following recommendations such as selection of appropriate functions, pharmacokinetic modeling, and sanity checks, this variability can be further reduced.
利用核医学成像进行患者特异性吸收剂量(AD)评估指导下的个体化放射性药物治疗,有提高疗效和安全性的潜力。了解AD计算中变异性的来源对于标准化至关重要。核医学与分子影像剂量学特别工作组发起了镥剂量学挑战,以评估剂量学工作流程中各步骤的变异性。这项工作旨在评估由于不同的拟合和积分方法导致的AD变异性。提供了两名接受镥-奥曲肽治疗患者的匿名数据集,包括系列SPECT/CT扫描、分割的器官和病变以及时间积分活度图,并在线提供。邀请参与者进行剂量学计算,并使用标准化的提交电子表格提交结果。对拟合方法进行分类,并使用四分位数离散系数和四分位间距分析相对AD变异性。患者A肾脏的拟合步骤导致的AD变异性小于1%。相比之下,患者B的肾脏显示出更高的变异性,值低于10%。病变在拟合中的变异性比肾脏更大,变异性在25%以内。对于健康器官,由拟合和积分引起的变异性贡献较小。通过遵循诸如选择合适的函数、药代动力学建模和合理性检查等建议,这种变异性可以进一步降低。